{Reference Type}: Journal Article {Title}: Interstitial lung disease in autoinflammatory disease in childhood: A systematic review of the literature. {Author}: Nayir Buyuksahin H;Basaran O;Balık Z;Bilginer Y;Ozen S;Dogru D; {Journal}: Pediatr Pulmonol {Volume}: 58 {Issue}: 2 {Year}: Feb 2023 {Factor}: 4.09 {DOI}: 10.1002/ppul.26220 {Abstract}: OBJECTIVE: The lung is one of the target organs in the systemic involvement of autoinflammatory disease (AID), and interstitial lung disease (ILD) is the primary phenotype of lung involvement in AID. In this review, we aimed to conduct a systematic review of the available literature to highlight ILD in AID.
METHODS: We conducted a systematic literature search in PubMed/MEDLINE and Scopus from the inception of the databases to January 2022. References were first screened by title and then by abstract by two authors. Eighteen original papers were selected for full-text review.
RESULTS: During the literature search, we identified 18 relevant articles describing 52 cases of AID and ILD. Of those, 44 patients had stimulator of interferon genes-associated vasculopathy with onset in infancy (SAVI), six had coatomer protein complex (COPA) syndrome, one had haploinsufficiency of A20, and one had mevalonate kinase deficiency. Pulmonary fibrosis, cyst formation, and ground glass areas were the most common findings in chest tomography of patients with COPA syndrome and SAVI. Janus kinase inhibitors were used to treat most of the patients with SAVI, which stabilized ILD.
CONCLUSIONS: ILD should be considered carefully in children with AID, especially those with interferonopathy.